Stellar Biotechnologies, Inc. (NASDAQ:SBOT) Releases Quarterly Earnings Results, Meets Expectations

Stellar Biotechnologies, Inc. (NASDAQ:SBOT) announced its earnings results on Wednesday. The biotechnology company reported ($0.12) EPS for the quarter, meeting the consensus estimate of ($0.12), Bloomberg Earnings reports. Stellar Biotechnologies had a negative return on equity of 46.97% and a negative net margin of 1,025.65%. The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.34 million.

Shares of Stellar Biotechnologies (SBOT) traded up 6.14% during midday trading on Friday, hitting $1.21. The stock had a trading volume of 21,850 shares. The firm’s 50-day moving average price is $1.31 and its 200-day moving average price is $1.45. Stellar Biotechnologies has a one year low of $1.05 and a one year high of $3.00. The firm’s market capitalization is $12.26 million.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.com-unik.info/2017/08/11/stellar-biotechnologies-inc-nasdaqsbot-releases-quarterly-earnings-results-meets-expectations.html.

About Stellar Biotechnologies

Stellar Biotechnologies, Inc is a biotechnology company. The Company is engaged in the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (KLH). KLH is an immune-stimulating protein. KLH can be used as an active pharmaceutical ingredient (API) and combined with a disease-targeting agent to create immunotherapies for the treatment of a range of diseases.

What are top analysts saying about Stellar Biotechnologies Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Stellar Biotechnologies Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit